Table 2.
Monoclonal Antibody | Targeted Site |
---|---|
Trastuzumab (Herceptin, Roche, Basel, Switzerland) | HER2 |
Bevacizumab (Avastin, Genentech, CA, USA) | VEGF-A |
Cetuximab (Erbitux, Kenilworth, NJ, USA) | EGFR |
Rituximab (Rituxan, Genentech, CA, USA) | CD20 |
Tositumomab (Bexxar, Genentech, CA, USA) | CD20 |
Ibritumomab tiuxetan (Zevalin, Biogen Idec, Cambridge, MA, USA) | CD20 |